nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—HTR2B—Sorafenib—kidney cancer	0.0831	0.157	CbGbCtD
Asenapine—HTR2C—Sorafenib—kidney cancer	0.0541	0.102	CbGbCtD
Asenapine—CYP2D6—Temsirolimus—kidney cancer	0.0532	0.101	CbGbCtD
Asenapine—CYP3A4—Everolimus—kidney cancer	0.0501	0.0946	CbGbCtD
Asenapine—CYP1A2—Pazopanib—kidney cancer	0.0339	0.0641	CbGbCtD
Asenapine—CYP3A4—Temsirolimus—kidney cancer	0.0338	0.0639	CbGbCtD
Asenapine—CYP2D6—Pazopanib—kidney cancer	0.028	0.0528	CbGbCtD
Asenapine—CYP1A2—Erlotinib—kidney cancer	0.0242	0.0457	CbGbCtD
Asenapine—CYP2D6—Erlotinib—kidney cancer	0.02	0.0377	CbGbCtD
Asenapine—CYP1A2—Sorafenib—kidney cancer	0.0197	0.0372	CbGbCtD
Asenapine—CYP3A4—Pazopanib—kidney cancer	0.0178	0.0336	CbGbCtD
Asenapine—CYP2D6—Sorafenib—kidney cancer	0.0162	0.0306	CbGbCtD
Asenapine—CYP2D6—Vinblastine—kidney cancer	0.016	0.0303	CbGbCtD
Asenapine—CYP3A4—Erlotinib—kidney cancer	0.0127	0.024	CbGbCtD
Asenapine—CYP3A4—Paclitaxel—kidney cancer	0.0116	0.0219	CbGbCtD
Asenapine—CYP3A4—Sorafenib—kidney cancer	0.0103	0.0195	CbGbCtD
Asenapine—CYP3A4—Vinblastine—kidney cancer	0.0102	0.0192	CbGbCtD
Asenapine—CYP3A4—Vincristine—kidney cancer	0.01	0.0189	CbGbCtD
Asenapine—CYP2D6—Doxorubicin—kidney cancer	0.00984	0.0186	CbGbCtD
Asenapine—CYP3A4—Sunitinib—kidney cancer	0.00836	0.0158	CbGbCtD
Asenapine—CYP3A4—Doxorubicin—kidney cancer	0.00626	0.0118	CbGbCtD
Asenapine—CYP1A2—urine—kidney cancer	0.00187	0.0857	CbGeAlD
Asenapine—UGT1A4—renal system—kidney cancer	0.0018	0.0824	CbGeAlD
Asenapine—UGT1A4—kidney—kidney cancer	0.00174	0.0797	CbGeAlD
Asenapine—HTR2A—urine—kidney cancer	0.00146	0.067	CbGeAlD
Asenapine—CYP3A4—urine—kidney cancer	0.00135	0.062	CbGeAlD
Asenapine—CYP2D6—urine—kidney cancer	0.00133	0.061	CbGeAlD
Asenapine—HRH2—cardiac atrium—kidney cancer	0.00101	0.0463	CbGeAlD
Asenapine—HTR1D—kidney—kidney cancer	0.000695	0.0319	CbGeAlD
Asenapine—HTR2B—cortex of kidney—kidney cancer	0.00063	0.0289	CbGeAlD
Asenapine—ADRB1—cardiac atrium—kidney cancer	0.000626	0.0287	CbGeAlD
Asenapine—HTR1A—renal system—kidney cancer	0.000599	0.0275	CbGeAlD
Asenapine—ADRA2C—nephron tubule—kidney cancer	0.000579	0.0266	CbGeAlD
Asenapine—HTR7—renal system—kidney cancer	0.000573	0.0263	CbGeAlD
Asenapine—HTR7—kidney—kidney cancer	0.000554	0.0254	CbGeAlD
Asenapine—ADRA1A—renal system—kidney cancer	0.000553	0.0254	CbGeAlD
Asenapine—ADRA2C—renal system—kidney cancer	0.000527	0.0242	CbGeAlD
Asenapine—HTR7—gonad—kidney cancer	0.000514	0.0236	CbGeAlD
Asenapine—ADRA2C—kidney—kidney cancer	0.000509	0.0234	CbGeAlD
Asenapine—ADRA2C—cortex of kidney—kidney cancer	0.000496	0.0227	CbGeAlD
Asenapine—ADRA2C—cardiac atrium—kidney cancer	0.000472	0.0216	CbGeAlD
Asenapine—CYP1A2—renal system—kidney cancer	0.000457	0.021	CbGeAlD
Asenapine—ADRA2A—cortex of kidney—kidney cancer	0.000396	0.0182	CbGeAlD
Asenapine—ADRA2A—gonad—kidney cancer	0.000377	0.0173	CbGeAlD
Asenapine—ADRA2A—cardiac atrium—kidney cancer	0.000376	0.0173	CbGeAlD
Asenapine—HTR2A—renal system—kidney cancer	0.000357	0.0164	CbGeAlD
Asenapine—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000356	0.00104	CcSEcCtD
Asenapine—Anaemia—Gemcitabine—kidney cancer	0.000355	0.00104	CcSEcCtD
Asenapine—Neutropenia—Capecitabine—kidney cancer	0.000355	0.00104	CcSEcCtD
Asenapine—Insomnia—Sunitinib—kidney cancer	0.000354	0.00103	CcSEcCtD
Asenapine—Nausea—Pazopanib—kidney cancer	0.000352	0.00103	CcSEcCtD
Asenapine—Mouth ulceration—Doxorubicin—kidney cancer	0.000352	0.00103	CcSEcCtD
Asenapine—Convulsion—Vincristine—kidney cancer	0.000351	0.00103	CcSEcCtD
Asenapine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000351	0.00103	CcSEcCtD
Asenapine—Fatigue—Sorafenib—kidney cancer	0.000351	0.00102	CcSEcCtD
Asenapine—Hypertension—Vincristine—kidney cancer	0.00035	0.00102	CcSEcCtD
Asenapine—Dyspnoea—Sunitinib—kidney cancer	0.000349	0.00102	CcSEcCtD
Asenapine—Constipation—Sorafenib—kidney cancer	0.000348	0.00102	CcSEcCtD
Asenapine—Malaise—Gemcitabine—kidney cancer	0.000347	0.00101	CcSEcCtD
Asenapine—Hypersensitivity—Vinblastine—kidney cancer	0.000346	0.00101	CcSEcCtD
Asenapine—Eye disorder—Paclitaxel—kidney cancer	0.000346	0.00101	CcSEcCtD
Asenapine—HTR2A—kidney—kidney cancer	0.000345	0.0158	CbGeAlD
Asenapine—Weight increased—Capecitabine—kidney cancer	0.000345	0.00101	CcSEcCtD
Asenapine—Hypersensitivity—Everolimus—kidney cancer	0.000345	0.00101	CcSEcCtD
Asenapine—Dyspepsia—Sunitinib—kidney cancer	0.000344	0.00101	CcSEcCtD
Asenapine—Leukopenia—Gemcitabine—kidney cancer	0.000344	0.00101	CcSEcCtD
Asenapine—Cardiac disorder—Paclitaxel—kidney cancer	0.000343	0.001	CcSEcCtD
Asenapine—Hyperglycaemia—Capecitabine—kidney cancer	0.000342	0.001	CcSEcCtD
Asenapine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000338	0.000987	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000337	0.000986	CcSEcCtD
Asenapine—Asthenia—Vinblastine—kidney cancer	0.000337	0.000986	CcSEcCtD
Asenapine—Fatigue—Sunitinib—kidney cancer	0.000337	0.000986	CcSEcCtD
Asenapine—Depression—Capecitabine—kidney cancer	0.000337	0.000986	CcSEcCtD
Asenapine—Asthenia—Everolimus—kidney cancer	0.000336	0.000982	CcSEcCtD
Asenapine—Angiopathy—Paclitaxel—kidney cancer	0.000336	0.000981	CcSEcCtD
Asenapine—Constipation—Sunitinib—kidney cancer	0.000335	0.000978	CcSEcCtD
Asenapine—Immune system disorder—Paclitaxel—kidney cancer	0.000334	0.000977	CcSEcCtD
Asenapine—Mediastinal disorder—Paclitaxel—kidney cancer	0.000333	0.000975	CcSEcCtD
Asenapine—Hypertension—Gemcitabine—kidney cancer	0.000332	0.000971	CcSEcCtD
Asenapine—Anaphylactic shock—Vincristine—kidney cancer	0.000331	0.000967	CcSEcCtD
Asenapine—CYP3A4—renal system—kidney cancer	0.000331	0.0152	CbGeAlD
Asenapine—Stomatitis—Capecitabine—kidney cancer	0.00033	0.000964	CcSEcCtD
Asenapine—Arthralgia—Gemcitabine—kidney cancer	0.000327	0.000957	CcSEcCtD
Asenapine—CYP2D6—renal system—kidney cancer	0.000325	0.0149	CbGeAlD
Asenapine—Diabetes mellitus—Doxorubicin—kidney cancer	0.000325	0.000951	CcSEcCtD
Asenapine—Nervous system disorder—Vincristine—kidney cancer	0.000325	0.000949	CcSEcCtD
Asenapine—Asthenia—Erlotinib—kidney cancer	0.000324	0.000948	CcSEcCtD
Asenapine—Mental disorder—Paclitaxel—kidney cancer	0.000324	0.000947	CcSEcCtD
Asenapine—Thrombocytopenia—Vincristine—kidney cancer	0.000324	0.000947	CcSEcCtD
Asenapine—Malnutrition—Paclitaxel—kidney cancer	0.000322	0.000941	CcSEcCtD
Asenapine—HTR2A—gonad—kidney cancer	0.00032	0.0147	CbGeAlD
Asenapine—Hepatobiliary disease—Capecitabine—kidney cancer	0.00032	0.000935	CcSEcCtD
Asenapine—CYP3A4—kidney—kidney cancer	0.00032	0.0147	CbGeAlD
Asenapine—Fatigue—Dactinomycin—kidney cancer	0.000319	0.000933	CcSEcCtD
Asenapine—Agranulocytosis—Capecitabine—kidney cancer	0.000316	0.000923	CcSEcCtD
Asenapine—Dysgeusia—Paclitaxel—kidney cancer	0.000315	0.000922	CcSEcCtD
Asenapine—CYP2D6—kidney—kidney cancer	0.000315	0.0144	CbGeAlD
Asenapine—Anaphylactic shock—Gemcitabine—kidney cancer	0.000314	0.000918	CcSEcCtD
Asenapine—Dizziness—Vinblastine—kidney cancer	0.000311	0.000909	CcSEcCtD
Asenapine—Dizziness—Everolimus—kidney cancer	0.00031	0.000905	CcSEcCtD
Asenapine—Muscle spasms—Paclitaxel—kidney cancer	0.00031	0.000905	CcSEcCtD
Asenapine—Hypotension—Vincristine—kidney cancer	0.000309	0.000904	CcSEcCtD
Asenapine—Nervous system disorder—Gemcitabine—kidney cancer	0.000308	0.0009	CcSEcCtD
Asenapine—Thrombocytopenia—Gemcitabine—kidney cancer	0.000307	0.000898	CcSEcCtD
Asenapine—Tremor—Paclitaxel—kidney cancer	0.000302	0.000882	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000301	0.000881	CcSEcCtD
Asenapine—Increased appetite—Doxorubicin—kidney cancer	0.000301	0.00088	CcSEcCtD
Asenapine—Hypersensitivity—Sorafenib—kidney cancer	0.0003	0.000876	CcSEcCtD
Asenapine—Insomnia—Vincristine—kidney cancer	0.000299	0.000875	CcSEcCtD
Asenapine—Oedema peripheral—Capecitabine—kidney cancer	0.000299	0.000874	CcSEcCtD
Asenapine—Vomiting—Vinblastine—kidney cancer	0.000299	0.000874	CcSEcCtD
Asenapine—Dizziness—Erlotinib—kidney cancer	0.000299	0.000874	CcSEcCtD
Asenapine—Connective tissue disorder—Capecitabine—kidney cancer	0.000298	0.000872	CcSEcCtD
Asenapine—Vomiting—Everolimus—kidney cancer	0.000298	0.000871	CcSEcCtD
Asenapine—Anaemia—Paclitaxel—kidney cancer	0.000298	0.00087	CcSEcCtD
Asenapine—Dermatitis bullous—Doxorubicin—kidney cancer	0.000296	0.000865	CcSEcCtD
Asenapine—Agitation—Paclitaxel—kidney cancer	0.000296	0.000865	CcSEcCtD
Asenapine—Rash—Everolimus—kidney cancer	0.000295	0.000863	CcSEcCtD
Asenapine—Dermatitis—Everolimus—kidney cancer	0.000295	0.000862	CcSEcCtD
Asenapine—Headache—Vinblastine—kidney cancer	0.000295	0.000861	CcSEcCtD
Asenapine—Angioedema—Paclitaxel—kidney cancer	0.000294	0.00086	CcSEcCtD
Asenapine—Headache—Everolimus—kidney cancer	0.000293	0.000858	CcSEcCtD
Asenapine—Hypotension—Gemcitabine—kidney cancer	0.000293	0.000857	CcSEcCtD
Asenapine—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000292	0.000854	CcSEcCtD
Asenapine—Asthenia—Sorafenib—kidney cancer	0.000292	0.000853	CcSEcCtD
Asenapine—Malaise—Paclitaxel—kidney cancer	0.00029	0.000849	CcSEcCtD
Asenapine—Syncope—Paclitaxel—kidney cancer	0.000289	0.000844	CcSEcCtD
Asenapine—Leukopenia—Paclitaxel—kidney cancer	0.000288	0.000843	CcSEcCtD
Asenapine—Hypersensitivity—Sunitinib—kidney cancer	0.000288	0.000843	CcSEcCtD
Asenapine—Vomiting—Erlotinib—kidney cancer	0.000287	0.00084	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000286	0.000836	CcSEcCtD
Asenapine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000286	0.000835	CcSEcCtD
Asenapine—Fatigue—Vincristine—kidney cancer	0.000285	0.000834	CcSEcCtD
Asenapine—Rash—Erlotinib—kidney cancer	0.000285	0.000833	CcSEcCtD
Asenapine—Dermatitis—Erlotinib—kidney cancer	0.000285	0.000832	CcSEcCtD
Asenapine—Hyponatraemia—Doxorubicin—kidney cancer	0.000284	0.00083	CcSEcCtD
Asenapine—Insomnia—Gemcitabine—kidney cancer	0.000284	0.00083	CcSEcCtD
Asenapine—Eye disorder—Capecitabine—kidney cancer	0.000284	0.000829	CcSEcCtD
Asenapine—Headache—Erlotinib—kidney cancer	0.000283	0.000828	CcSEcCtD
Asenapine—Loss of consciousness—Paclitaxel—kidney cancer	0.000283	0.000827	CcSEcCtD
Asenapine—Constipation—Vincristine—kidney cancer	0.000283	0.000827	CcSEcCtD
Asenapine—Pain in extremity—Doxorubicin—kidney cancer	0.000283	0.000827	CcSEcCtD
Asenapine—Osteoarthritis—Doxorubicin—kidney cancer	0.000283	0.000827	CcSEcCtD
Asenapine—Cardiac disorder—Capecitabine—kidney cancer	0.000282	0.000824	CcSEcCtD
Asenapine—Asthenia—Sunitinib—kidney cancer	0.000281	0.000821	CcSEcCtD
Asenapine—Dyspnoea—Gemcitabine—kidney cancer	0.00028	0.000818	CcSEcCtD
Asenapine—Nausea—Vinblastine—kidney cancer	0.000279	0.000816	CcSEcCtD
Asenapine—Somnolence—Gemcitabine—kidney cancer	0.000279	0.000816	CcSEcCtD
Asenapine—Convulsion—Paclitaxel—kidney cancer	0.000279	0.000816	CcSEcCtD
Asenapine—Nausea—Everolimus—kidney cancer	0.000278	0.000813	CcSEcCtD
Asenapine—Hypertension—Paclitaxel—kidney cancer	0.000278	0.000813	CcSEcCtD
Asenapine—Angiopathy—Capecitabine—kidney cancer	0.000275	0.000805	CcSEcCtD
Asenapine—Immune system disorder—Capecitabine—kidney cancer	0.000274	0.000802	CcSEcCtD
Asenapine—Arthralgia—Paclitaxel—kidney cancer	0.000274	0.000801	CcSEcCtD
Asenapine—Mediastinal disorder—Capecitabine—kidney cancer	0.000274	0.0008	CcSEcCtD
Asenapine—Anxiety—Paclitaxel—kidney cancer	0.000273	0.000799	CcSEcCtD
Asenapine—Hypersensitivity—Dactinomycin—kidney cancer	0.000273	0.000798	CcSEcCtD
Asenapine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000271	0.000792	CcSEcCtD
Asenapine—Fatigue—Gemcitabine—kidney cancer	0.000271	0.000791	CcSEcCtD
Asenapine—Dizziness—Sorafenib—kidney cancer	0.000269	0.000786	CcSEcCtD
Asenapine—Constipation—Gemcitabine—kidney cancer	0.000268	0.000785	CcSEcCtD
Asenapine—Nausea—Erlotinib—kidney cancer	0.000268	0.000785	CcSEcCtD
Asenapine—Dry mouth—Paclitaxel—kidney cancer	0.000268	0.000784	CcSEcCtD
Asenapine—Mental disorder—Capecitabine—kidney cancer	0.000266	0.000777	CcSEcCtD
Asenapine—Asthenia—Dactinomycin—kidney cancer	0.000266	0.000777	CcSEcCtD
Asenapine—Malnutrition—Capecitabine—kidney cancer	0.000264	0.000773	CcSEcCtD
Asenapine—Anaphylactic shock—Paclitaxel—kidney cancer	0.000263	0.000768	CcSEcCtD
Asenapine—Dysgeusia—Capecitabine—kidney cancer	0.000259	0.000757	CcSEcCtD
Asenapine—Dizziness—Sunitinib—kidney cancer	0.000259	0.000756	CcSEcCtD
Asenapine—Shock—Paclitaxel—kidney cancer	0.000259	0.000756	CcSEcCtD
Asenapine—Vomiting—Sorafenib—kidney cancer	0.000259	0.000756	CcSEcCtD
Asenapine—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000258	0.000755	CcSEcCtD
Asenapine—Nervous system disorder—Paclitaxel—kidney cancer	0.000258	0.000753	CcSEcCtD
Asenapine—Thrombocytopenia—Paclitaxel—kidney cancer	0.000257	0.000752	CcSEcCtD
Asenapine—Tachycardia—Paclitaxel—kidney cancer	0.000257	0.00075	CcSEcCtD
Asenapine—Rash—Sorafenib—kidney cancer	0.000256	0.000749	CcSEcCtD
Asenapine—Dermatitis—Sorafenib—kidney cancer	0.000256	0.000749	CcSEcCtD
Asenapine—Breast disorder—Doxorubicin—kidney cancer	0.000256	0.000747	CcSEcCtD
Asenapine—Headache—Sorafenib—kidney cancer	0.000255	0.000745	CcSEcCtD
Asenapine—Muscle spasms—Capecitabine—kidney cancer	0.000254	0.000743	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000249	0.000729	CcSEcCtD
Asenapine—Vomiting—Sunitinib—kidney cancer	0.000249	0.000727	CcSEcCtD
Asenapine—Tremor—Capecitabine—kidney cancer	0.000248	0.000724	CcSEcCtD
Asenapine—Rash—Sunitinib—kidney cancer	0.000247	0.000721	CcSEcCtD
Asenapine—Dermatitis—Sunitinib—kidney cancer	0.000246	0.00072	CcSEcCtD
Asenapine—Hypotension—Paclitaxel—kidney cancer	0.000246	0.000718	CcSEcCtD
Asenapine—Headache—Sunitinib—kidney cancer	0.000245	0.000716	CcSEcCtD
Asenapine—Dysphagia—Doxorubicin—kidney cancer	0.000244	0.000715	CcSEcCtD
Asenapine—Anaemia—Capecitabine—kidney cancer	0.000244	0.000714	CcSEcCtD
Asenapine—Hypersensitivity—Vincristine—kidney cancer	0.000244	0.000713	CcSEcCtD
Asenapine—Nausea—Sorafenib—kidney cancer	0.000241	0.000706	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000239	0.0007	CcSEcCtD
Asenapine—Malaise—Capecitabine—kidney cancer	0.000238	0.000697	CcSEcCtD
Asenapine—Insomnia—Paclitaxel—kidney cancer	0.000238	0.000695	CcSEcCtD
Asenapine—Asthenia—Vincristine—kidney cancer	0.000237	0.000694	CcSEcCtD
Asenapine—Syncope—Capecitabine—kidney cancer	0.000237	0.000693	CcSEcCtD
Asenapine—Leukopenia—Capecitabine—kidney cancer	0.000237	0.000691	CcSEcCtD
Asenapine—Vomiting—Dactinomycin—kidney cancer	0.000235	0.000688	CcSEcCtD
Asenapine—Dyspnoea—Paclitaxel—kidney cancer	0.000234	0.000685	CcSEcCtD
Asenapine—Somnolence—Paclitaxel—kidney cancer	0.000234	0.000683	CcSEcCtD
Asenapine—Rash—Dactinomycin—kidney cancer	0.000234	0.000683	CcSEcCtD
Asenapine—Nausea—Sunitinib—kidney cancer	0.000232	0.000679	CcSEcCtD
Asenapine—Loss of consciousness—Capecitabine—kidney cancer	0.000232	0.000679	CcSEcCtD
Asenapine—Dyspepsia—Paclitaxel—kidney cancer	0.000231	0.000676	CcSEcCtD
Asenapine—Neutropenia—Doxorubicin—kidney cancer	0.000229	0.000668	CcSEcCtD
Asenapine—Hypertension—Capecitabine—kidney cancer	0.000228	0.000667	CcSEcCtD
Asenapine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000227	0.000663	CcSEcCtD
Asenapine—Fatigue—Paclitaxel—kidney cancer	0.000227	0.000662	CcSEcCtD
Asenapine—Asthenia—Gemcitabine—kidney cancer	0.000225	0.000658	CcSEcCtD
Asenapine—Arthralgia—Capecitabine—kidney cancer	0.000225	0.000658	CcSEcCtD
Asenapine—Constipation—Paclitaxel—kidney cancer	0.000225	0.000657	CcSEcCtD
Asenapine—Anxiety—Capecitabine—kidney cancer	0.000224	0.000655	CcSEcCtD
Asenapine—Weight increased—Doxorubicin—kidney cancer	0.000222	0.00065	CcSEcCtD
Asenapine—Hyperglycaemia—Doxorubicin—kidney cancer	0.000221	0.000645	CcSEcCtD
Asenapine—Dry mouth—Capecitabine—kidney cancer	0.00022	0.000643	CcSEcCtD
Asenapine—Nausea—Dactinomycin—kidney cancer	0.00022	0.000643	CcSEcCtD
Asenapine—Dizziness—Vincristine—kidney cancer	0.000219	0.00064	CcSEcCtD
Asenapine—Stomatitis—Doxorubicin—kidney cancer	0.000212	0.000621	CcSEcCtD
Asenapine—Shock—Capecitabine—kidney cancer	0.000212	0.00062	CcSEcCtD
Asenapine—Nervous system disorder—Capecitabine—kidney cancer	0.000212	0.000618	CcSEcCtD
Asenapine—Thrombocytopenia—Capecitabine—kidney cancer	0.000211	0.000617	CcSEcCtD
Asenapine—Tachycardia—Capecitabine—kidney cancer	0.00021	0.000615	CcSEcCtD
Asenapine—Vomiting—Vincristine—kidney cancer	0.00021	0.000615	CcSEcCtD
Asenapine—Rash—Vincristine—kidney cancer	0.000209	0.00061	CcSEcCtD
Asenapine—Dermatitis—Vincristine—kidney cancer	0.000208	0.000609	CcSEcCtD
Asenapine—Headache—Vincristine—kidney cancer	0.000207	0.000606	CcSEcCtD
Asenapine—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000206	0.000603	CcSEcCtD
Asenapine—Agranulocytosis—Doxorubicin—kidney cancer	0.000203	0.000595	CcSEcCtD
Asenapine—Hypotension—Capecitabine—kidney cancer	0.000202	0.000589	CcSEcCtD
Asenapine—Vomiting—Gemcitabine—kidney cancer	0.0002	0.000583	CcSEcCtD
Asenapine—Rash—Gemcitabine—kidney cancer	0.000198	0.000579	CcSEcCtD
Asenapine—Dermatitis—Gemcitabine—kidney cancer	0.000198	0.000578	CcSEcCtD
Asenapine—Headache—Gemcitabine—kidney cancer	0.000197	0.000575	CcSEcCtD
Asenapine—Nausea—Vincristine—kidney cancer	0.000197	0.000575	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000197	0.000574	CcSEcCtD
Asenapine—Insomnia—Capecitabine—kidney cancer	0.000195	0.00057	CcSEcCtD
Asenapine—Hypersensitivity—Paclitaxel—kidney cancer	0.000194	0.000566	CcSEcCtD
Asenapine—Oedema peripheral—Doxorubicin—kidney cancer	0.000193	0.000564	CcSEcCtD
Asenapine—Connective tissue disorder—Doxorubicin—kidney cancer	0.000192	0.000562	CcSEcCtD
Asenapine—Dyspnoea—Capecitabine—kidney cancer	0.000192	0.000562	CcSEcCtD
Asenapine—Dyspepsia—Capecitabine—kidney cancer	0.00019	0.000555	CcSEcCtD
Asenapine—Asthenia—Paclitaxel—kidney cancer	0.000189	0.000551	CcSEcCtD
Asenapine—Nausea—Gemcitabine—kidney cancer	0.000186	0.000545	CcSEcCtD
Asenapine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000186	0.000544	CcSEcCtD
Asenapine—Fatigue—Capecitabine—kidney cancer	0.000186	0.000544	CcSEcCtD
Asenapine—Constipation—Capecitabine—kidney cancer	0.000184	0.000539	CcSEcCtD
Asenapine—Eye disorder—Doxorubicin—kidney cancer	0.000183	0.000535	CcSEcCtD
Asenapine—Cardiac disorder—Doxorubicin—kidney cancer	0.000182	0.000531	CcSEcCtD
Asenapine—Angiopathy—Doxorubicin—kidney cancer	0.000178	0.000519	CcSEcCtD
Asenapine—Immune system disorder—Doxorubicin—kidney cancer	0.000177	0.000517	CcSEcCtD
Asenapine—Mediastinal disorder—Doxorubicin—kidney cancer	0.000176	0.000516	CcSEcCtD
Asenapine—Dizziness—Paclitaxel—kidney cancer	0.000174	0.000508	CcSEcCtD
Asenapine—Mental disorder—Doxorubicin—kidney cancer	0.000171	0.000501	CcSEcCtD
Asenapine—Malnutrition—Doxorubicin—kidney cancer	0.00017	0.000498	CcSEcCtD
Asenapine—Vomiting—Paclitaxel—kidney cancer	0.000167	0.000488	CcSEcCtD
Asenapine—Dysgeusia—Doxorubicin—kidney cancer	0.000167	0.000488	CcSEcCtD
Asenapine—Rash—Paclitaxel—kidney cancer	0.000166	0.000484	CcSEcCtD
Asenapine—Dermatitis—Paclitaxel—kidney cancer	0.000166	0.000484	CcSEcCtD
Asenapine—Headache—Paclitaxel—kidney cancer	0.000165	0.000481	CcSEcCtD
Asenapine—Muscle spasms—Doxorubicin—kidney cancer	0.000164	0.000479	CcSEcCtD
Asenapine—Hypersensitivity—Capecitabine—kidney cancer	0.000159	0.000465	CcSEcCtD
Asenapine—Anaemia—Doxorubicin—kidney cancer	0.000157	0.00046	CcSEcCtD
Asenapine—Agitation—Doxorubicin—kidney cancer	0.000157	0.000458	CcSEcCtD
Asenapine—Nausea—Paclitaxel—kidney cancer	0.000156	0.000456	CcSEcCtD
Asenapine—Asthenia—Capecitabine—kidney cancer	0.000155	0.000452	CcSEcCtD
Asenapine—Malaise—Doxorubicin—kidney cancer	0.000154	0.000449	CcSEcCtD
Asenapine—Syncope—Doxorubicin—kidney cancer	0.000153	0.000447	CcSEcCtD
Asenapine—Leukopenia—Doxorubicin—kidney cancer	0.000152	0.000446	CcSEcCtD
Asenapine—Loss of consciousness—Doxorubicin—kidney cancer	0.00015	0.000438	CcSEcCtD
Asenapine—Convulsion—Doxorubicin—kidney cancer	0.000148	0.000431	CcSEcCtD
Asenapine—Hypertension—Doxorubicin—kidney cancer	0.000147	0.00043	CcSEcCtD
Asenapine—Arthralgia—Doxorubicin—kidney cancer	0.000145	0.000424	CcSEcCtD
Asenapine—Anxiety—Doxorubicin—kidney cancer	0.000145	0.000422	CcSEcCtD
Asenapine—Dizziness—Capecitabine—kidney cancer	0.000143	0.000417	CcSEcCtD
Asenapine—Dry mouth—Doxorubicin—kidney cancer	0.000142	0.000415	CcSEcCtD
Asenapine—Anaphylactic shock—Doxorubicin—kidney cancer	0.000139	0.000406	CcSEcCtD
Asenapine—Vomiting—Capecitabine—kidney cancer	0.000137	0.000401	CcSEcCtD
Asenapine—Shock—Doxorubicin—kidney cancer	0.000137	0.0004	CcSEcCtD
Asenapine—Nervous system disorder—Doxorubicin—kidney cancer	0.000136	0.000399	CcSEcCtD
Asenapine—Thrombocytopenia—Doxorubicin—kidney cancer	0.000136	0.000398	CcSEcCtD
Asenapine—Rash—Capecitabine—kidney cancer	0.000136	0.000398	CcSEcCtD
Asenapine—Dermatitis—Capecitabine—kidney cancer	0.000136	0.000397	CcSEcCtD
Asenapine—Tachycardia—Doxorubicin—kidney cancer	0.000136	0.000397	CcSEcCtD
Asenapine—Headache—Capecitabine—kidney cancer	0.000135	0.000395	CcSEcCtD
Asenapine—Hypotension—Doxorubicin—kidney cancer	0.00013	0.00038	CcSEcCtD
Asenapine—Nausea—Capecitabine—kidney cancer	0.000128	0.000374	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000127	0.00037	CcSEcCtD
Asenapine—Insomnia—Doxorubicin—kidney cancer	0.000126	0.000368	CcSEcCtD
Asenapine—Dyspnoea—Doxorubicin—kidney cancer	0.000124	0.000362	CcSEcCtD
Asenapine—Somnolence—Doxorubicin—kidney cancer	0.000124	0.000361	CcSEcCtD
Asenapine—Dyspepsia—Doxorubicin—kidney cancer	0.000122	0.000358	CcSEcCtD
Asenapine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.00012	0.000351	CcSEcCtD
Asenapine—Fatigue—Doxorubicin—kidney cancer	0.00012	0.00035	CcSEcCtD
Asenapine—Constipation—Doxorubicin—kidney cancer	0.000119	0.000348	CcSEcCtD
Asenapine—Hypersensitivity—Doxorubicin—kidney cancer	0.000102	0.000299	CcSEcCtD
Asenapine—Asthenia—Doxorubicin—kidney cancer	9.97e-05	0.000292	CcSEcCtD
Asenapine—Dizziness—Doxorubicin—kidney cancer	9.19e-05	0.000269	CcSEcCtD
Asenapine—Vomiting—Doxorubicin—kidney cancer	8.84e-05	0.000258	CcSEcCtD
Asenapine—Rash—Doxorubicin—kidney cancer	8.77e-05	0.000256	CcSEcCtD
Asenapine—Dermatitis—Doxorubicin—kidney cancer	8.76e-05	0.000256	CcSEcCtD
Asenapine—Headache—Doxorubicin—kidney cancer	8.71e-05	0.000255	CcSEcCtD
Asenapine—Nausea—Doxorubicin—kidney cancer	8.26e-05	0.000241	CcSEcCtD
Asenapine—HTR2A—Signaling by GPCR—KRAS—kidney cancer	6.41e-06	6.01e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—MYC—kidney cancer	6.41e-06	6.01e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—MAPK3—kidney cancer	6.4e-06	6e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—MYC—kidney cancer	6.4e-06	6e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—KRAS—kidney cancer	6.4e-06	6e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MTOR—kidney cancer	6.39e-06	5.99e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—BRAF—kidney cancer	6.37e-06	5.97e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—MYC—kidney cancer	6.36e-06	5.96e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—BCHE—kidney cancer	6.36e-06	5.96e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—VEGFA—kidney cancer	6.36e-06	5.96e-05	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	6.35e-06	5.95e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—IL2—kidney cancer	6.34e-06	5.94e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CDKN1B—kidney cancer	6.34e-06	5.94e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—MAPK3—kidney cancer	6.3e-06	5.91e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—IL2—kidney cancer	6.29e-06	5.89e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—SLC5A5—kidney cancer	6.28e-06	5.89e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	6.28e-06	5.88e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—MAPK1—kidney cancer	6.27e-06	5.88e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—MAPK1—kidney cancer	6.26e-06	5.87e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—MYC—kidney cancer	6.23e-06	5.84e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—MAPK1—kidney cancer	6.22e-06	5.83e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—ABCB1—kidney cancer	6.21e-06	5.82e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—IL2—kidney cancer	6.21e-06	5.82e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	6.2e-06	5.81e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—CCND1—kidney cancer	6.18e-06	5.8e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	6.18e-06	5.79e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—JUN—kidney cancer	6.17e-06	5.78e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	6.17e-06	5.78e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PTGS2—kidney cancer	6.15e-06	5.77e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—MYC—kidney cancer	6.13e-06	5.74e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—CCND1—kidney cancer	6.13e-06	5.74e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	6.12e-06	5.74e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—JUN—kidney cancer	6.11e-06	5.73e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—MAPK1—kidney cancer	6.09e-06	5.71e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	6.07e-06	5.69e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—IL2—kidney cancer	6.07e-06	5.69e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—SLC2A1—kidney cancer	6.07e-06	5.69e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CCND1—kidney cancer	6.05e-06	5.67e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—JUN—kidney cancer	6.04e-06	5.66e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—IL2—kidney cancer	6.04e-06	5.66e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—GSTM1—kidney cancer	6.03e-06	5.65e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—MAPK3—kidney cancer	6.02e-06	5.64e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	6e-06	5.62e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—VEGFA—kidney cancer	6e-06	5.62e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—MAPK1—kidney cancer	6e-06	5.62e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CTNNB1—kidney cancer	5.99e-06	5.61e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	5.99e-06	5.61e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PTEN—kidney cancer	5.97e-06	5.59e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—RAF1—kidney cancer	5.94e-06	5.57e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—KRAS—kidney cancer	5.92e-06	5.55e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—VEGFA—kidney cancer	5.92e-06	5.54e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—KRAS—kidney cancer	5.92e-06	5.54e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—RELA—kidney cancer	5.92e-06	5.54e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CCND1—kidney cancer	5.91e-06	5.54e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PTEN—kidney cancer	5.91e-06	5.54e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—JUN—kidney cancer	5.9e-06	5.53e-05	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	5.9e-06	5.53e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	5.89e-06	5.52e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CCND1—kidney cancer	5.88e-06	5.51e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—ERBB2—kidney cancer	5.88e-06	5.51e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	5.88e-06	5.51e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—KRAS—kidney cancer	5.88e-06	5.51e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—JUN—kidney cancer	5.87e-06	5.5e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—IL2—kidney cancer	5.87e-06	5.5e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	5.86e-06	5.49e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—MYC—kidney cancer	5.85e-06	5.48e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—RAF1—kidney cancer	5.85e-06	5.48e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PTEN—kidney cancer	5.84e-06	5.47e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—RAF1—kidney cancer	5.83e-06	5.47e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	5.83e-06	5.47e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	5.83e-06	5.46e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—RELA—kidney cancer	5.82e-06	5.45e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—RELA—kidney cancer	5.81e-06	5.44e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MTOR—kidney cancer	5.8e-06	5.44e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—ERBB2—kidney cancer	5.78e-06	5.42e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—ERBB2—kidney cancer	5.77e-06	5.41e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	5.77e-06	5.4e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—KRAS—kidney cancer	5.75e-06	5.39e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—RAF1—kidney cancer	5.72e-06	5.36e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CCND1—kidney cancer	5.72e-06	5.36e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—MAPK1—kidney cancer	5.72e-06	5.36e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—CYP1A1—kidney cancer	5.71e-06	5.35e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—JUN—kidney cancer	5.71e-06	5.35e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PTEN—kidney cancer	5.71e-06	5.35e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MTOR—kidney cancer	5.71e-06	5.35e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—RELA—kidney cancer	5.7e-06	5.34e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MTOR—kidney cancer	5.7e-06	5.34e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PTEN—kidney cancer	5.68e-06	5.32e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—MAPK3—kidney cancer	5.67e-06	5.32e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	5.67e-06	5.31e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	5.66e-06	5.31e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—KRAS—kidney cancer	5.66e-06	5.31e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—MAPK3—kidney cancer	5.6e-06	5.25e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MTOR—kidney cancer	5.59e-06	5.24e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PTEN—kidney cancer	5.52e-06	5.18e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—MYC—kidney cancer	5.52e-06	5.17e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—MYC—kidney cancer	5.44e-06	5.1e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CDKN1B—kidney cancer	5.44e-06	5.1e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—PIK3CA—kidney cancer	5.44e-06	5.1e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—PIK3CA—kidney cancer	5.43e-06	5.09e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—KRAS—kidney cancer	5.41e-06	5.07e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	5.4e-06	5.06e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—MAPK1—kidney cancer	5.4e-06	5.06e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—VEGFA—kidney cancer	5.39e-06	5.05e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PTEN—kidney cancer	5.37e-06	5.03e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	5.36e-06	5.02e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	5.36e-06	5.02e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CDKN1B—kidney cancer	5.34e-06	5.01e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	5.34e-06	5.01e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—IL2—kidney cancer	5.33e-06	4.99e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—MAPK1—kidney cancer	5.33e-06	4.99e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—RAF1—kidney cancer	5.32e-06	4.98e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—RELA—kidney cancer	5.3e-06	4.96e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	5.29e-06	4.95e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—VEGFA—kidney cancer	5.27e-06	4.94e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—TP53—kidney cancer	5.26e-06	4.93e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	5.26e-06	4.93e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—TP53—kidney cancer	5.26e-06	4.93e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	5.24e-06	4.92e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—IL2—kidney cancer	5.24e-06	4.91e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—IL2—kidney cancer	5.23e-06	4.9e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—TP53—kidney cancer	5.22e-06	4.9e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—PIK3CA—kidney cancer	5.2e-06	4.88e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CCND1—kidney cancer	5.19e-06	4.87e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MTOR—kidney cancer	5.19e-06	4.87e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—JUN—kidney cancer	5.18e-06	4.86e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—VEGFA—kidney cancer	5.16e-06	4.83e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CTNNB1—kidney cancer	5.14e-06	4.82e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL2—kidney cancer	5.13e-06	4.81e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—VEGFA—kidney cancer	5.13e-06	4.81e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—kidney cancer	5.11e-06	4.79e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CCND1—kidney cancer	5.11e-06	4.79e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MAPK3—kidney cancer	5.1e-06	4.78e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—JUN—kidney cancer	5.1e-06	4.78e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CCND1—kidney cancer	5.1e-06	4.78e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—kidney cancer	5.1e-06	4.78e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—JUN—kidney cancer	5.09e-06	4.77e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	5.06e-06	4.74e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTP1—kidney cancer	5.06e-06	4.74e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	5.05e-06	4.74e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CTNNB1—kidney cancer	5.05e-06	4.73e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—kidney cancer	5.03e-06	4.72e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—kidney cancer	5.03e-06	4.71e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—POMC—kidney cancer	5.03e-06	4.71e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PTEN—kidney cancer	5.01e-06	4.7e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CCND1—kidney cancer	5e-06	4.69e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—JUN—kidney cancer	4.99e-06	4.68e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	4.99e-06	4.68e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MAPK3—kidney cancer	4.99e-06	4.68e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—PIK3CA—kidney cancer	4.97e-06	4.65e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MYC—kidney cancer	4.96e-06	4.65e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	4.95e-06	4.64e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PTEN—kidney cancer	4.93e-06	4.62e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PTEN—kidney cancer	4.92e-06	4.61e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MYC—kidney cancer	4.91e-06	4.61e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MAPK3—kidney cancer	4.88e-06	4.57e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	4.87e-06	4.57e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MAPK3—kidney cancer	4.85e-06	4.55e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MAPK1—kidney cancer	4.85e-06	4.55e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MYC—kidney cancer	4.85e-06	4.55e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PTEN—kidney cancer	4.83e-06	4.53e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	4.81e-06	4.51e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—kidney cancer	4.8e-06	4.5e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ABCB1—kidney cancer	4.79e-06	4.49e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL2—kidney cancer	4.77e-06	4.47e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MAPK1—kidney cancer	4.75e-06	4.45e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MYC—kidney cancer	4.74e-06	4.45e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	4.72e-06	4.42e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MYC—kidney cancer	4.72e-06	4.42e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.69e-06	4.4e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—PIK3CA—kidney cancer	4.68e-06	4.39e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PIK3CA—kidney cancer	4.66e-06	4.37e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTM1—kidney cancer	4.65e-06	4.36e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCND1—kidney cancer	4.65e-06	4.36e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MAPK1—kidney cancer	4.64e-06	4.35e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—JUN—kidney cancer	4.64e-06	4.35e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—PIK3CA—kidney cancer	4.62e-06	4.33e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MAPK1—kidney cancer	4.62e-06	4.33e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	4.6e-06	4.31e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MYC—kidney cancer	4.59e-06	4.3e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—kidney cancer	4.58e-06	4.3e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—kidney cancer	4.54e-06	4.26e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—kidney cancer	4.53e-06	4.25e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—VEGFA—kidney cancer	4.53e-06	4.24e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	4.49e-06	4.21e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PTEN—kidney cancer	4.49e-06	4.21e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—kidney cancer	4.48e-06	4.2e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—kidney cancer	4.47e-06	4.19e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—VEGFA—kidney cancer	4.45e-06	4.17e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—VEGFA—kidney cancer	4.45e-06	4.17e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CYP1A1—kidney cancer	4.41e-06	4.13e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—kidney cancer	4.38e-06	4.11e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	4.36e-06	4.09e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—kidney cancer	4.36e-06	4.09e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK3—kidney cancer	4.28e-06	4.01e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—POMC—kidney cancer	4.26e-06	3.99e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—kidney cancer	4.24e-06	3.98e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK3—kidney cancer	4.21e-06	3.95e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	4.21e-06	3.95e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK3—kidney cancer	4.2e-06	3.94e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	4.17e-06	3.91e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MYC—kidney cancer	4.17e-06	3.9e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	4.13e-06	3.87e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PIK3CA—kidney cancer	4.12e-06	3.86e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MYC—kidney cancer	4.1e-06	3.84e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MYC—kidney cancer	4.09e-06	3.83e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK1—kidney cancer	4.08e-06	3.82e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—kidney cancer	4.07e-06	3.82e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	4.05e-06	3.8e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—kidney cancer	4.04e-06	3.78e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	4.03e-06	3.77e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MYC—kidney cancer	4.01e-06	3.76e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK1—kidney cancer	4.01e-06	3.76e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTGS2—kidney cancer	4.01e-06	3.76e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	4.01e-06	3.76e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK1—kidney cancer	4e-06	3.75e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—kidney cancer	3.98e-06	3.73e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	3.93e-06	3.68e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	3.9e-06	3.65e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—kidney cancer	3.9e-06	3.65e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—kidney cancer	3.88e-06	3.63e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—kidney cancer	3.85e-06	3.61e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	3.83e-06	3.59e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—kidney cancer	3.79e-06	3.55e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PIK3CA—kidney cancer	3.79e-06	3.55e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—kidney cancer	3.78e-06	3.54e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—kidney cancer	3.77e-06	3.53e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MYC—kidney cancer	3.73e-06	3.49e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—kidney cancer	3.71e-06	3.48e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	3.65e-06	3.42e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PIK3CA—kidney cancer	3.54e-06	3.31e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTEN—kidney cancer	3.5e-06	3.28e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	3.48e-06	3.26e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PIK3CA—kidney cancer	3.47e-06	3.25e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—kidney cancer	3.45e-06	3.23e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—kidney cancer	3.42e-06	3.21e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	3.41e-06	3.19e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTGS2—kidney cancer	3.4e-06	3.18e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—kidney cancer	3.37e-06	3.15e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—kidney cancer	3.36e-06	3.15e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—kidney cancer	3.3e-06	3.09e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—POMC—kidney cancer	3.29e-06	3.08e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	3.17e-06	2.97e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—kidney cancer	3.06e-06	2.87e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTEN—kidney cancer	2.96e-06	2.78e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTGS2—kidney cancer	2.62e-06	2.46e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.47e-06	2.31e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTEN—kidney cancer	2.29e-06	2.14e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.09e-06	1.96e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.61e-06	1.51e-05	CbGpPWpGaD
